AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 214 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,519,254 | -20.1% | 61,384 | -8.6% | 0.00% | -33.3% |
| Q2 2023 | $1,900,952 | +29.9% | 67,124 | +5.3% | 0.00% | +50.0% |
| Q1 2023 | $1,463,924 | -19.4% | 63,732 | -1.5% | 0.00% | -33.3% |
| Q4 2022 | $1,816,271 | +0.4% | 64,682 | +1.1% | 0.00% | 0.0% |
| Q3 2022 | $1,809,000 | +24.4% | 63,981 | -2.5% | 0.00% | +50.0% |
| Q2 2022 | $1,454,000 | -23.0% | 65,601 | +1.1% | 0.00% | 0.0% |
| Q1 2022 | $1,889,000 | -22.9% | 64,881 | -12.9% | 0.00% | -33.3% |
| Q4 2021 | $2,449,000 | -31.4% | 74,513 | -3.6% | 0.00% | -40.0% |
| Q3 2021 | $3,569,000 | -23.7% | 77,330 | -8.9% | 0.01% | -16.7% |
| Q2 2021 | $4,679,000 | -15.3% | 84,910 | -20.7% | 0.01% | -14.3% |
| Q1 2021 | $5,526,000 | +18.7% | 107,008 | -0.4% | 0.01% | 0.0% |
| Q4 2020 | $4,655,000 | +25.8% | 107,436 | +1.7% | 0.01% | +16.7% |
| Q3 2020 | $3,699,000 | -33.2% | 105,691 | +2.1% | 0.01% | -40.0% |
| Q2 2020 | $5,538,000 | +55.7% | 103,546 | +3.3% | 0.01% | +25.0% |
| Q1 2020 | $3,557,000 | -20.9% | 100,241 | +6.4% | 0.01% | 0.0% |
| Q4 2019 | $4,499,000 | +68.7% | 94,223 | +14.5% | 0.01% | +60.0% |
| Q3 2019 | $2,667,000 | -34.8% | 82,302 | +0.4% | 0.01% | -37.5% |
| Q2 2019 | $4,090,000 | -24.2% | 82,000 | +2.5% | 0.01% | -27.3% |
| Q1 2019 | $5,396,000 | +46.9% | 80,018 | +0.4% | 0.01% | +37.5% |
| Q4 2018 | $3,674,000 | -39.1% | 79,684 | +1.9% | 0.01% | -33.3% |
| Q3 2018 | $6,028,000 | -8.5% | 78,160 | -0.0% | 0.01% | -14.3% |
| Q2 2018 | $6,586,000 | +6.0% | 78,185 | +2.9% | 0.01% | +7.7% |
| Q1 2018 | $6,216,000 | +64.4% | 76,008 | +14.9% | 0.01% | +62.5% |
| Q4 2017 | $3,781,000 | -15.5% | 66,141 | -1.3% | 0.01% | -20.0% |
| Q3 2017 | $4,475,000 | +17.3% | 67,038 | -9.6% | 0.01% | +25.0% |
| Q2 2017 | $3,816,000 | +6.4% | 74,157 | +20.7% | 0.01% | +14.3% |
| Q1 2017 | $3,588,000 | +33.6% | 61,441 | -4.5% | 0.01% | +40.0% |
| Q4 2016 | $2,685,000 | -23.0% | 64,341 | -2.6% | 0.01% | -28.6% |
| Q3 2016 | $3,488,000 | +38.9% | 66,041 | +10.2% | 0.01% | +40.0% |
| Q2 2016 | $2,511,000 | +12.6% | 59,941 | +9.1% | 0.01% | 0.0% |
| Q1 2016 | $2,230,000 | -28.3% | 54,918 | +14.7% | 0.01% | -37.5% |
| Q4 2015 | $3,109,000 | -6.5% | 47,892 | +1.7% | 0.01% | -11.1% |
| Q3 2015 | $3,324,000 | -36.6% | 47,092 | -0.2% | 0.01% | -30.8% |
| Q2 2015 | $5,245,000 | +107.1% | 47,192 | +75.8% | 0.01% | +116.7% |
| Q1 2015 | $2,532,000 | -17.1% | 26,849 | -1.5% | 0.01% | -14.3% |
| Q4 2014 | $3,053,000 | +98.8% | 27,249 | +8.8% | 0.01% | +75.0% |
| Q3 2014 | $1,536,000 | +35.2% | 25,042 | +1.0% | 0.00% | +33.3% |
| Q2 2014 | $1,136,000 | +134.2% | 24,800 | +100.0% | 0.00% | +200.0% |
| Q1 2014 | $485,000 | +63.3% | 12,400 | 0.0% | 0.00% | 0.0% |
| Q4 2013 | $297,000 | +8.4% | 12,400 | +26.5% | 0.00% | 0.0% |
| Q3 2013 | $274,000 | – | 9,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |